Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Melanoma

Free Subscription 22.07.2024 2 Am J Dermatopathol 2 Ann Surg Oncol 1 Biochem Biophys Res Commun 1 BMC Cancer 2 Br J Dermatol 2 Clin Cancer Res 1 Eur J Dermatol 2 Int J Cancer 2 J Am Acad Dermatol 1 Melanoma Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Dermatopathol

1. FIELDS BC, Jain AJ, Prieto VG, Frink SJ, et al
   Pigmented Villonodular Synovitis: A Metastatic Melanoma Imitator.
   Am J Dermatopathol. 2024 Jul 12. doi: 10.1097/DAD.0000000000002771.
   PubMed         Abstract available
   
   
2. IBRAHIM E, Yang RK, Curry JL, Cho WC, et al
   BCR::ZNF711 and BCR::CYLC2 Fusions: Novel BCR Fusions Expanding the Molecular Spectrum of Gene Fusions in Melanoma.
   Am J Dermatopathol. 2024 Jul 12. doi: 10.1097/DAD.0000000000002796.
   PubMed        
   
   

   
   Ann Surg Oncol

3. ZAGER JS, Orloff M, Ferrucci PF, Choi J, et al
   Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
   Ann Surg Oncol. 2024 Jul 18. doi: 10.1245/s10434-024-15886.
   PubMed        
   
   
4. MONTGOMERY KB, Holder AM, Broman KK
   ASO Author Reflections: Synoptic Reporting for Melanoma Nodal Surveillance Ultrasonography.
   Ann Surg Oncol. 2024 Jul 16. doi: 10.1245/s10434-024-15735.
   PubMed        
   
   

   
   Biochem Biophys Res Commun

5. YU X, Li M, Wang C, Guan X, et al
   Glycoprotein non-metastatic melanoma protein B (GPNMB): An attractive target in atherosclerosis.
   Biochem Biophys Res Commun. 2024;732:150386.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. YIN W, Li R, Zhang Z, Wang Y, et al
   Causal association between skin cancer and immune cells: mendelian randomization (MR) study.
   BMC Cancer. 2024;24:849.
   PubMed         Abstract available
   
   

   
   Br J Dermatol

7. LINDSAY D, Bell KJL, Olsen CM, Whiteman DC, et al
   Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia.
   Br J Dermatol. 2024 Jul 19:ljae296. doi: 10.1093.
   PubMed         Abstract available
   
   
8. OLSEN CM, Pandeya N, Neale RE, Law MH, et al
   Phenotypic and genotypic risk factors for invasive melanoma by sex and body site.
   Br J Dermatol. 2024 Jul 19:ljae297. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

9. YAKKALA C, Corria-Osorio J, Kandalaft L, Denys A, et al
   Cryoablation does not significantly contribute to systemic effector immune responses in poorly immunogenic B16F10 melanoma model.
   Clin Cancer Res. 2024 Jul 18. doi: 10.1158/1078-0432.CCR-24-0371.
   PubMed         Abstract available
   
   
10. ZHAO Y, Hu Z, Bathena SP, Keidel S, et al
    Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.
    Clin Cancer Res. 2024;30:3050-3058.
    PubMed         Abstract available
    
    

    
    Eur J Dermatol

11. YOON S, Lee SY, Lee GJ, Kim JS, et al
    Psoriasis and in situ or invasive non-melanoma skin cancer: a bidirectional Mendelian randomisation study.
    Eur J Dermatol. 2024;34:314-317.
    PubMed        
    
    

    
    Int J Cancer

12. FORSCHNER A, Nanz L, Maczey-Leber Y, Amaral T, et al
    Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition.
    Int J Cancer. 2024 Jul 20. doi: 10.1002/ijc.35103.
    PubMed         Abstract available
    
    
13. TURNER JA, Van Gulick RJ, Robinson WA, Mughal T, et al
    Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.
    Int J Cancer. 2024 Jul 12. doi: 10.1002/ijc.35087.
    PubMed         Abstract available
    
    

    
    J Am Acad Dermatol

14. FRIEDMAN A
    JAAD Game Changers: "Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort".
    J Am Acad Dermatol. 2024 Jul 17:S0190-9622(24)02501.
    PubMed        
    
    
15. TUPPER CJ, Cogua LM, Silberstein PT
    Increasing Survival for Melanoma with Bony Metastases in the Era of Novel Therapies: A Population-Based Retrospective Analysis.
    J Am Acad Dermatol. 2024 Jul 16:S0190-9622(24)02493.
    PubMed        
    
    

    
    Melanoma Res

16. CHANDRASEKARAN S, Ling YL, Tang J
    Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States.
    Melanoma Res. 2024 Jul 16. doi: 10.1097/CMR.0000000000000990.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.